文献速递肝病消化道出血

卡维地洛联合辛伐他汀对严重门静脉高压且对β受体阻滞剂应答不佳的肝硬化患者的血流动力学影响:双盲、安慰剂对照、随机试验

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial.
PubMed 文献 · Hepatology · 2024-11-07

这项双盲随机安慰剂对照试验纳入184例高危静脉曲张的肝硬化患者,82例对传统非选择性β受体阻滞剂(NSBB)应答不佳者随机接受卡维地洛联合辛伐他汀或卡维地洛联合安慰剂。联合辛伐他汀组肝静脉压力梯度(HVPG)下降幅度更大(2.97±2.5 vs 2.05±1.6 mm Hg,p=0.031),HVPG下降≥20%的比例更高(37% vs 15%,OR 3.37,95%CI 1.15-9.85,p=0.021),且餐后HVPG增幅更小、炎症因子下降更显著,不良事件发生率相似。

要点

  • 对传统NSBB应答不佳的肝硬化伴高危静脉曲张患者,卡维地洛联合辛伐他汀较单药进一步降低HVPG。
  • 联合辛伐他汀组HVPG下降≥20%的患者比例为37%,安慰剂组为15%(OR 3.37,95%CI 1.15-9.85)。
  • 联合辛伐他汀可减轻餐后HVPG升高并降低炎症因子水平,不良事件发生率与安慰剂组相似。

核心结论

  • 在严重门静脉高压(均伴高危静脉曲张)且对传统NSBB血流动力学应答不佳的患者中,卡维地洛联合辛伐他汀较卡维地洛单药显著增强门静脉压力下降、改善内皮功能障碍并降低促炎细胞因子。

研究设计与样本

  • 双盲、安慰剂对照、随机试验,连续纳入因高危静脉曲张接受一级预防的肝硬化患者,基线及静脉注射普萘洛尔后测HVPG,应答不佳者(HVPG下降<20%)接受卡维地洛并随机加用安慰剂或辛伐他汀。
  • 184例合格患者中82例随机分组:卡维地洛联合辛伐他汀组41例,卡维地洛联合安慰剂组41例;4-6周后评估慢性HVPG应答,并在标准流质餐后重复测HVPG以评估内皮功能障碍。

主要发现

  • HVPG在卡维地洛联合辛伐他汀组由18.6±4降至15.7±4 mm Hg(p<0.001),在卡维地洛联合安慰剂组由18.9±3降至16.9±3 mm Hg(p<0.001)。
  • HVPG下降幅度联合辛伐他汀组为2.97±2.5 mm Hg,安慰剂组为2.05±1.6 mm Hg(p=0.031)。
  • HVPG下降≥20%者联合辛伐他汀组为37%,安慰剂组为15%(OR 3.37,95%CI 1.15-9.85;p=0.021)。
  • 标准餐后两组HVPG均升高(p<0.01),联合辛伐他汀组增幅为12±8%,安慰剂组为23±16%(p<0.001)。
  • 白细胞介素-6、单核细胞趋化蛋白-1和丙二醛水平在联合辛伐他汀组下降更显著(p<0.01);不良事件发生率两组相似。

关键数值与推荐

  • HVPG应答不佳定义为静脉注射普萘洛尔后HVPG下降<20%。
  • 慢性HVPG应答在治疗4-6周后评估,并于标准流质餐后重复测量HVPG。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Carvedilol is a nonselective β-blocker (NSBB) with anti-α1-adrenergic activity, more effective than traditional NSBBs in reducing portal pressure hepatic venous pressure gradient (HVPG). However, 35%-45% of patients still have insufficient HVPG decrease. Statins ameliorate endothelial dysfunction, reduce hepatic vascular resistance, and have pleiotropic effects. We investigated whether the addition of simvastatin improves the efficacy of carvedilol on HVPG in cirrhosis with severe portal hypertension and suboptimal response to traditional NSBBs. METHODS: Patients with cirrhosis and high-risk varices referred for primary prophylaxis were consecutively included. HVPG was measured at baseline and again after i.v. propranolol. Suboptimal responders (HVPG decrease <20%) were treated with carvedilol and were randomized to double-blind administration of placebo or simvastatin. Chronic HVPG response was assessed after 4-6 weeks, repeating HVPG measurements after a standard liquid meal to estimate endothelial dysfunction. Plasma samples were obtained before each study to investigate inflammatory parameters. RESULTS: Of 184 eligible patients, 82 were randomized to carvedilol + simvastatin (N = 41) or carvedilol + placebo (N = 41). Baseline characteristics were similar. HVPG significantly decreased with both, carvedilol + simvastatin (18.6 ± 4 to 15.7 ± 4 mm Hg, p < 0.001) and carvedilol + placebo (18.9 ± 3 to 16.9 ± 3 mm Hg, p < 0.001). The decrease was greater with carvedilol + simvastatin (2.97 ± 2.5 vs. 2.05 ± 1.6 mm Hg, p = 0.031). An HVPG decrease ≥20% occurred in 37% versus 15% of patients, respectively (OR: 3.37, 95% CI = 1.15-9.85; p = 0.021). With test meal, HVPG increased in both groups ( p < 0.01), although carvedilol + simvastatin attenuated such increment (12 ± 8% vs. 23 ± 16%, p < 0.001). Cytokine levels (Interleukine-6, monocyte-chemoattractant protein-1, and malondialdehyde) decreased significantly more with carvedilol + simvastatin ( p < 0.01). The incidence of adverse events was similar. CONCLUSIONS: In patients with severe portal hypertension (all with high-risk varices) and suboptimal hemodynamic response to traditional NSBBs, combined therapy with carvedilol plus simvastatin significantly enhances the portal pressure reduction achieved with carvedilol monotherapy, improves endothelial dysfunction, and reduces proinflammatory cytokines.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Alvarado-Tapias E, Brujats A, Puente A, et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial. Hepatology. 2024. PMID: 39509369. doi:10.1097/HEP.0000000000001148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。